Proprietary sustained-release dexamethasone implant shows promise for treating persistent cystoid macular edema

Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.